Who Paid My Doc
Ashley Shrives
Nurse Practitioner Weiner, AR Nurse Practitioner
NPI 1003352444 CMS profile 11109145
106 N Van Buren St, Weiner, AR 72479
General payments
$14
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ashley Shrives of Weiner, AR is reported in the CMS Open Payments database as having received $14 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $14 | 1 |
Beside peers
- Ashley Shrives
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Ashley Shrives were reported at $14. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Ashley Shrives | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $0 | $135 | $40–$426 | $132 |
| 2022 | $0 | $152 | $48–$470 | $149 |
| 2023 | $0 | $166 | $54–$529 | $160 |
| 2024 | $0 | $173 | $55–$556 | $164 |
| 2025 | $14 | $174 | $55–$557 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
42
Drug cost
$758
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Doxycycline Hyclate | Generic | 12 | $390 | |
| Mupirocin | Generic | 19 | $258 | |
| Triamcinolone Acetonide | Generic | 11 | $109 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in Arkansas
Merideth Hanks
Nurse Practitioner · Rogers, AR
Angela Jones
Nurse Practitioner · Jonesboro, AR
Tiffany McConathy
Nurse Practitioner · Hot Springs, AR
Brenna Fitzgerald
Nurse Practitioner · North Little Rock, AR
Iris Kennedy
Nurse Practitioner · Little Rock, AR
Virginia Laliberte
Nurse Practitioner · Hot Springs, AR
Related records
Nurse Practitioner in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.